1059P - Phase I study of nivolumab (nivo) + nab-paclitaxel (nab-P) in solid tumors: results from the pancreatic cancer (PC) and non-small cell lung cancer...

Date 09 October 2016
Event ESMO 2016 Congress
Session Poster display
Topics Immunotherapy
Presenter Ben George
Citation Annals of Oncology (2016) 27 (6): 359-378. 10.1093/annonc/mdw378
Authors B. George1, K. Kelly2, A. Ko3, H. Soliman4, N. Trunova5, Z. Wainberg6, D. Waterhouse7, P. O'Dwyer8, H. Hochster9
  • 1Division Of Hematology And Oncology, Froedtert and the Medical College of Wisconsin, 53226 - Milwaukee/US
  • 2Internal Medicine, UC Davis Comprehensive Cancer Center, Sacramento/US
  • 3Biostats, Celgene Corporation, Summit/US
  • 4Hematology, Women’s Oncology and Experimental Therapeutics and University of South Florida, Moffitt Cancer Center, Tampa/US
  • 5Medical Affairs, Celgene Corporation, Summit/US
  • 6Internal Medicine, David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles/US
  • 7Medical Oncology, Oncology Hematology Care, Cincinnati/US
  • 8Medicine, University of Pennsylvania, Abramson Cancer Center, Philadelphia/US
  • 9Medical Oncology, Yale Cancer Center, New Haven/US



Combining a taxane with an immune checkpoint inhibitor has demonstrated improved response across multiple tumors. Here we present interim results from the PC and NSCLC cohorts of a phase I safety trial of nivo + nab-P in advanced NSCLC (+ carboplatin [C]), advanced PC (± gemcitabine [G]), and metastatic breast cancer.


The primary objective of part 1 is to evaluate dose-limiting toxicities (DLTs). Patients (pts) treated with ≥ 2 cycles of nivo with chemotherapy (CT) and remained on study for 14 calendar days or who discontinued due to DLT prior to completing 2 cycles of nivo were considered DLT evaluable. If deemed safe, treatment arms will be expanded in Part 2 to further assess safety, tolerability, and antitumor activity. In Arm A Part 1, pts with advanced PC and 1 prior chemotherapy (CT) regimen received nab-P 125 mg/m2 on D 1, 8, and 15 (qw 3/4) + nivo 3 mg/kg on D 1 and 15 of a 28-day cycle. If Arm A is safe, a cohort of CT-naive pts will be enrolled in Arm B and treated with nab-P + G 1000 mg/m2 qw 3/4 + nivo. In Arm C, treatment-naive pts with stage IIIB/IV NSCLC received 4 cycles of nab-P 100 mg/m2 on D 1, 8, and 15 + C AUC 6 on D 1 + nivo 5 mg/kg on D 15 of a 21-day cycle. If Arm C is safe, pts in Arm D will receive the Arm C regimen, except nivo will start at cycle 3. In both NSCLC arms, nivo monotherapy begins at cycle 5.


As of Apr 21, 2016, 11 and 20 pts have been treated in Arms A and C. In Arm A, at the time of DLT evaluation (Dec 21, 2015), no DLTs were observed, and no grade 3/4 adverse events (AEs) occurred in > 1 pt. Of the 8 response evaluable pts, 2 achieved a partial response (PR). In Arm C, no DLTs were observed at the time of DLT evaluation (Nov 9, 2015). Of the 14 nivo-treated, response evaluable pts in Arm C, 7 had a PR, and 7 had stable disease. Grade 2 pneumonitis was reported in 1 pt but resolved, and the pt continued on the study. The most common any-grade AEs in either arm were fatigue, nausea, and alopecia.


Addition of nivo to nab-P or nab-P/C was tolerable with no DLTs or unexpected AEs in Arms A or C. Efficacy data in Arm C, although preliminary and unconfirmed, is encouraging. Arm B is currently enrolling pts with advanced PC for first-line treatment with nivo + nab-P + G.

Clinical trial identification


Legal entity responsible for the study

Ben George, MD


Celgene Corporation


B. George: Consultant to Celgene Corporation. A. Ko, N. Trunova: Employee of Celgene Corporation. H. Soliman: Advisory role, Celgene. D. Waterhouse: Consultant or advisory role, BMS and Eli Lilly, speakers bureau, BMS, Celgene, Eli Lilly, Genentech/Roche. P. O'Dwyer: consultant: Five Prime Therapeutics; Genentech research funding: BBI Healthcare; Bristol-Myers Squibb; Celgene; Genentech; GlaxoSmithKline; Mirati Therapeutics; Novartis; Pfizer; stock: TetraLogic; expert testimony: Lilly. H. Hochster: consultant: Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim, Genentech, Amgen, Sirtex Medical, Bristol-Myers Squibb; speakers bureau: Genomic Health. All other authors have declared no conflicts of interest.